CHF Solutions Announces COVID-19 Patients Treated with Aquadex Therapy for Fluid Management When Access to Dialysis Machines ...
April 14 2020 - 8:00AM
CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to
changing the lives of patients suffering from fluid overload,
announced that physicians on the frontlines of treating patients
with COVID-19 have used Aquadex therapy for patients who need fluid
removal between dialysis treatments as an alternative therapy when
dialysis machines or trained dialysis personnel are not
available. In addition, patients hemodynamically unstable and
fluid overloaded, who may not be able to tolerate dialysis but
still need fluid removal, are being treated with the Aquadex
therapy.
The real-world case studies and related discussion were
presented during a physician-led webinar hosted by CHF Solutions on
April 10. Dr. Daniel J. Goldstein, MD, FACS, FACC (Montefiore
Medical Center, NY, NY) moderated the panel discussion which
included Dr. Maria DeVita, M.D., FACP, FASN (Lenox Hill Hospital,
NY, NY), Dr. Mehdi Oloomi, M.D. (Mount Sinai Medical Center, NY,
NY) and Dr. Giovanni Piovesana (Phoebe-Putney Hospital, Albany,
GA).
The physicians’ discussion and recommendations were supported by
a recent article published by the Clinical Journal of the American
Society of Nephrology.1 In the publication, the authors concluded,
“the use of other machines to replace a standard dialysis machine
may have merit such as machines that only do isolated
ultrafiltration to perform all isolated ultrafiltration procedures,
thereby keeping standard full-size dialysis machines available to
perform treatments.”
“Acute kidney injury is a significant risk for critically ill
patients with COVID-19,” said Dr. DeVita. “Adequate access to
dialysis equipment is a growing concern as is the growing number of
patients who need fluid removal but are poor candidates for
traditional dialysis. We see ultrafiltration as a valuable
treatment in both instances and are seeing a clear benefit to
including Aquadex therapy as a vital part of our armamentarium to
treat COVID-19.”
“As we continue to learn about this novel virus, it is important
that we listen to the dedicated medical professionals treating
patients on the front line. We are pleased that Aquadex therapy can
help critical care patients during this pandemic,” said John Erb,
CEO of CHF Solutions. “As previously announced, we have increased
production to meet anticipated demand and ensure that physicians,
nurses and the clinical staff have the solutions they need to treat
patients impacted with COVID-19. I also want to take this
opportunity to thank our customers for their continued partnership
with us as they find ways to treat those affected by the
coronavirus and extend our most sincere gratitude to the first
responders and medical teams taking care of the critically ill
patients.”
1.CJASN ePress. Dwyer, et
al. published on April 3, 2020 as doi: 10.2215/CJN.03750320
About CHF Solutions CHF Solutions, Inc.
(Nasdaq: CHFS) is a medical device company dedicated to improving
the lives of patients suffering from fluid overload with its novel
ultrafiltration therapy system. The company is focused on
developing, manufacturing and commercializing the Aquadex
SmartFlow™ system for ultrafiltration therapy. CHF Solutions is
headquartered in Minneapolis, Minn., with wholly-owned subsidiaries
in Australia and Ireland. The company has been listed on the Nasdaq
Capital Market since February 2012.
About the Aquadex SmartFlow System The Aquadex
SmartFlow system delivers clinically proven therapy using a simple,
flexible and smart method of removing excess fluid from patients
suffering from hypervolemia (fluid overload). The Aquadex SmartFlow
system is indicated for temporary (up to 8 hours) or extended
(longer than 8 hours in patients who require hospitalization) use
in adult and pediatric patients weighing 20 kg or more whose fluid
overload is unresponsive to medical management, including
diuretics. All treatments must be administered by a health care
provider, within an outpatient or inpatient clinical setting,
un
Forward-Looking Statements Certain statements
in this release may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation, statements about the clinical
use of the Aquadex SmartFlow system in patients infected with the
coronavirus COVID-19. Forward-looking statements are predictions,
projections and other statements about future events that are based
on current expectations and assumptions and, as a result, are
subject to risks and uncertainties. Many factors could cause actual
future events to differ materially from the forward-looking
statements in this release, including, without limitation, those
risk associated with our ability to execute on our commercial
strategy, the possibility that we may be unable to raise sufficient
funds necessary for our anticipated operations, our post-market
clinical data collection activities, benefits of our products to
patients, our expectations with respect to product development and
commercialization efforts, our ability to increase market and
physician acceptance of our products, potentially competitive
product offerings, intellectual property protection, our ability to
integrate acquired businesses, our expectations regarding
anticipated synergies with and benefits from acquired businesses,
and other risks and uncertainties described in our filings with the
SEC. Forward-looking statements speak only as of the date when
made. CHF Solutions does not assume any obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
CONTACTS
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer, CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
MEDIA:
Jessica Stebing
Health+Commerce
260-336-6202
jstebing@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Aug 2024 to Sep 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Sep 2023 to Sep 2024